BMS CA209-7A8: A randomized, non-comparative neoadjuvant phase II study in patients with ER+/HER2- breast cancer >2 cm with safety run-in, assessing nivolumab + palbociclib + anastrazole (Checkmate 7A8)
The purpose of this study is to test the effectiveness, safety and tolerability of nivolumab (Opdivo), with palbociclib (Ibrance) and anastrazole (Arimidex) in patients newly diagnosed with hormone-receptor positive (ER+) and human epidermal growth factor receptor 2 (HER2) negative breast cancer.
Principal Investigator
William MacLaughlin, MD
Contact
Ora Mae Jackson, RN, OCN
757-534-5565
[email protected]
Locations
Peninsula Cancer Institute
12100 Warwick Blvd, Suite 201
Newport News, VA 23601
Cancer Specialists of Tidewater
110-E Wimbledon Square
Chesapeake, VA 23320
Cancer Specialists of Tidewater
1200 First Colonial Road
Virginia Beach, VA 23454
Status
Recruiting
Category
Oncology
Study #